卡瑞利珠单抗联合吉西他滨顺铂一线治疗复发或转移性鼻咽癌的III期随机双盲试验
CAPTAIN-1st研究是一项在中国28家医院开展的随机双盲III期试验,比较卡瑞利珠单抗或安慰剂联合吉西他滨和顺铂一线治疗复发或转移性鼻咽癌。结果表明该联合方案可能成为新的一线标准治疗,但需更长随访确认。
要点
- 卡瑞利珠单抗联合吉西他滨和顺铂显著改善复发/转移性鼻咽癌一线无进展生存。
- ≥3级不良事件常见,但两组发生率相似;治疗相关死亡卡瑞利珠单抗组5例(4%)。
核心结论
- 卡瑞利珠单抗联合吉西他滨和顺铂可能成为复发或转移性鼻咽癌一线治疗的新标准,需更长随访确认。
研究设计与样本
- 随机、双盲、III期试验,在中国28家医院进行。
- 纳入263例既往未治疗的复发或转移性鼻咽癌患者,按1:1随机分配至卡瑞利珠单抗组(n=134)或安慰剂组(n=129)。
- 分层因素包括肝转移、既往根治性同步放化疗和ECOG体能状态。
主要发现
- 最常见≥3级不良事件(任何原因):白细胞计数减少(卡瑞利珠单抗组89例[66%] vs 安慰剂组90例[70%])、中性粒细胞计数减少(86例[64%] vs 85例[66%])、贫血(53例[40%] vs 57例[44%])、血小板计数减少(53例[40%] vs 52例[40%])。
- 严重不良事件:卡瑞利珠单抗组59例(44%)vs 安慰剂组48例(37%)。
- 治疗相关死亡:卡瑞利珠单抗组5例(4%),安慰剂组1例(<1%)。
临床怎么用
- 对于既往未治疗的复发或转移性鼻咽癌患者,可考虑卡瑞利珠单抗联合吉西他滨和顺铂一线治疗。
- 治疗期间需密切监测≥3级血液学毒性及严重不良事件。
局限性
- 研究在中国进行,结果外推需谨慎。
- 需更长随访确认结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of camrelizumab to gemcitabine and cisplatin showed promising activity as first-line therapy in patients with recurrent or metastatic nasopharyngeal carcinoma in a phase 1 trial. We therefore compared camrelizumab plus gemcitabine and cisplatin with placebo plus gemcitabine and cisplatin in a randomised phase 3 trial. METHODS: In this randomised, double-blind, phase 3 trial done at 28 hospitals in China, patients were eligible if they were aged 18-75 years, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, and had previously untreated recurrent or metastatic nasopharyngeal carcinoma. Patients were randomly assigned (1:1; using an interactive web-response system with a block size of four) to receive either camrelizumab (200 mg on day 1) or matching placebo intravenously, plus gemcitabine and cisplatin (gemcitabine 1000 mg/m2 on days 1 and 8; cisplatin 80 mg/m2 on day 1) intravenously every 3 weeks for four to six cycles, followed by maintenance therapy with camrelizumab or placebo, until radiographic progression, unacceptable toxicity, start of new anticancer treatment, investigator decision, or withdrawal of consent. Stratification factors used in randomisation were liver metastases, previous radical concurrent chemoradiotherapy, and ECOG performance status. The allocation sequence was generated by an independent randomisation group. The primary endpoint was progression-free survival per independent review committee. The significance threshold for independent review committee-assessed progression-free survival was p=0·0086 (one-sided) at the interim analysis. Efficacy and safety analyses included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03707509, and is closed for enrolment but is ongoing. FINDINGS: Between Nov 13, 2018, and Nov 29, 2019, 343 patients were screened and 263 were eligible and were randomly assigned to the camrelizumab group (n=134) or placebo group (n=129). At the prespecified interim analysis (June 15, 2020), independent review committee-assessed progression-free survival was significantly longer in the camrelizumab group (median 9·7 months [95% CI 8·3-11·4]) than in the placebo group (median 6·9 months [5·9-7·3]; hazard ratio 0·54 [95% CI 0·39-0·76]; one-sided p=0·0002). As of Dec 31, 2020, the most common grade 3 or worse adverse events of any cause were decreased white blood cell count (89 [66%] of 134 patients in the camrelizumab group vs 90 [70%] of 129 patients in the placebo group), decreased neutrophil count (86 [64%] vs 85 [66%]), anaemia (53 [40%] vs 57 [44%]), and decreased platelet count (53 [40%] vs 52 [40%]). Serious adverse events were reported in 59 (44%) of 134 patients in the camrelizumab group and 48 (37%) of 129 patients in the placebo group. Treatment-related deaths occurred in five (4%) patients in the camrelizumab group (two unknown cause of death, one multiple organ dysfunction syndrome, one pharyngeal haemorrhage, and one arrhythmia) and one (<1%) patient in the placebo group (unknown cause of death). INTERPRETATION: Our findings suggest that camrelizumab plus gemcitabine and cisplatin could be a new standard of care for patients with recurrent or metastatic nasopharyngeal carcinoma in the first-line setting. Longer follow-up is needed to confirm this conclusion. FUNDING: Jiangsu Hengrui Pharmaceuticals (formerly Jiangsu Hengrui Medicine). TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021. PMID: 34174189. doi:10.1016/S1470-2045(21)00302-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。